A systematic review and meta-analysis of randomized controlled trials to evaluate the risk of health-related quality of life events in patients with hormone receptor-positive her2-negative metastatic breast cancer treated with CDK 4/6 inhibitors

Authors
Category Systematic review
JournalJNCCN Journal of the National Comprehensive Cancer Network
Year 2019
This article has no abstract
Epistemonikos ID: 4aa4c5380146836171c81414aa118d59caff8d5a
First added on: Feb 11, 2025